Progress and problems in the biology, diagnostics, and therapeutics of prion diseases

Journal of Clinical Investigation

Volumn 114, Issue 2, 2004, Pages 153-160

  Aguzzi, Adriano ^a,b   Heikenwalder, Mathias ^a   Miele, Gino ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; ADHESIN; AMPHOTERICIN B; AMYLOIDOTROPIC INTERCALATING AGENT; ANTHRACYCLINE DERIVATIVE; CHLORPROMAZINE; CONGO RED; CURCUMIN; CYTIDYLGUANYL OLIGODEOXYNUCLEOTIDE; ERYTHROID DIFFERENTIATION RELATED FACTOR; INTERCALATING AGENT; LYMPHOTOXIN; MEPACRINE; NEURON SPECIFIC ENOLASE; OLIGODEOXYNUCLEOTIDE; POLYAMINE; POLYANION; POLYENE ANTIBIOTIC AGENT; PORPHYRIN; PRION PROTEIN; PRION PROTEIN ANTIBODY; PROTEIN 14 3 3; PROTEIN S 100; RECEPTOR; SMALL INTERFERING RNA; SOLUBLE DIMERIC PRION PROTEIN IMMUNOADHESION; SOLUBLE LYMPHOTOXIN RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS ANTIBODY;

BOVINE SPONGIFORM ENCEPHALOPATHY; CHEMICAL SYMPATHECTOMY; CHRONIC WASTING DISEASE; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; DISEASE MARKER; DRUG MECHANISM; FOLLICULAR DENDRITIC CELL; HUMAN; IMMUNOLOGICAL SYMPATHECTOMY; NERVE DEGENERATION; NEUROIMAGING; NEUROINVASION; NEUROPATHOLOGY; NONHUMAN; PRION DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; SCRAPIE; SYMPATHECTOMY; VACCINATION; VIRUS INFECTIVITY; VIRUS REPLICATION;

EID: 4043181415     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI22438     Document Type: Review

References (95)

1. Glatzel, M., et al. 2003. Human prion diseases: epidemiology and integrated risk assessment. Lancet Neurol. 2:757-763.
2. Collins, P.S., Lawson, V.A., and Masters, P.C. 2004. Transmissible spongiform encephalopathies. Lancet. 363:51-61.
3. Bolton, D.C., McKinley, M.P., and Prusiner, S.B. 1982. Identification of a protein that purifies with the scrapie prion. Science. 218:1309-1311.
4. Safar, J.G., et al. 2002. Measuring prions causing bovine spongiform encephalopathy or chronic wasting disease by immunoassays and transgenic mice. Nat. Biotechnol. 20:1147-1150.
5. Creutzfeldt, H.G. 1920. Über eine eigenartige herdförmige Erkrankung des Zentralnervensystems. Zeitschrift für die gesamte Neurologie und Psychiatrie. 57:1-19.
6. Jakob, A. 1921. Über eigenartige Erkrankungen des Zentralnervensystems mit bemerkenswertem anatomischem Befunde. (Spastische Pseudosklerose-Encephalomyelopathie mit disseminierten Degenerationsherden). Zeitschrift für die gesamte Neurologie und Psychiatrie. 64:147-228.
7. Griffith, J.S. 1967. Self-replication and scrapie. Nature. 215:1043-1044.
8. Prusiner, S.B. 1982. Novel proteinaceous infectious particles cause scrapie. Science. 216:136-144.
9. Weissmann, C. 1991. A 'unified theory' of prion propagation. Nature. 352:679-683.
10. Telling, G.C., et al. 1995. Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell. 83:79-90.
11. Priola, S.A., Chesebro, B., and Caughey, B. 2003. Biomedicine. A view from the top-prion diseases from 10,000 feet. Science. 300:917-919.
12. Glatzel, M., Abela, E., Maissen, M., and Aguzzi, A. 2003. Extraneural pathologic prion protein in sporadic Creutzfeldt-Jakob disease. N. Engl. J. Med. 349:1812-1820.
13. Hill, A.F., et al. 2003. Molecular classification of sporadic Creutzfeldt-Jakob disease. Brain. 126:1333-1346.
14. Aguzzi, A., Montrasio, F., and Kaeser, P.S. 2001. Prions: health scare and biological challenge. Nat. Rev. Mol. Cell Biol. 2:118-126.
15. Brown, K.L., et al. 1999. Scrapie replication in lymphoid tissues depends on prion protein-expressing follicular dendritic cells. Nat. Med. 5:1308-1312.
16. Aguzzi, A. 2003. Prions and the immune system: a journey through gut, spleen, and nerves. Adv. Immunol. 81:123-171.
17. Mabbort, N.A., Young, J., McConnell, I., and Bruce, M.E. 2003. Follicular dendriric cell dedifferentiation by treatment with an inhibitor of the lymphotoxin pathway dramatically reduces scrapie susceptibility. J. Virol. 77:6845-6854.
18. Prinz, M., et al. 2003. Oral prion infection requires normal numbers of Peyer's patches but not of enreric lymphocytes. Am. J. Pathol. 162:1103-1111.
19. Büeler, H.R., et al. 1993. Mice devoid of PrP are resistant to scrapie. Cell. 73:1339-1347.
20. Brandner, S., et al. 1996. Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature. 379:339-343.
21. Blättler, T., et al. 1997. PrP-expressing tissue required for transfer of scrapie infectivity from spleen to brain. Nature. 389:69-73.
22. Brandner, S., et al. 1996. Normal host prion prorein (PrPC) is required for scrapie spread within the central nervous system. Proc. Natl. Acad. Sci. U. S. A. 93:13148-13151.
23. Kaeser, P.S., Klein, M.A., Schwarz, P., and Aguzzi, A. 2001. Efficient lymphoreticular prion propagation requires prp(c) in srromal and hematopoietic cells. J. Virol. 75:7097-7106.
24. Klein, M.A., et al. 1997. A crucial role for B cells in neuroinvasive scrapie. Nature. 390:687-690.
25. Klein, M.A., et al. 1998. PrP expression in B lymphocytes is not required for prion neuroinvasion. Nat. Med. 4:1429-1433.
26. Montrasio, F., et al. 2001. B lymphocyte-resrricted expression of prion protein does not enable prion replication in prion protein knockout mice. Proc. Natl. Acad. Sci. U. S. A. 98:4034-4037.
27. Kitamoto, T., Muramoto, T., Mohri, S., Doh-Ura, K., and Tateishi, J. 1991. Abnormal isoform of prion protein accumulates in follicular dendritic cells in mice with Creurzfeldt-Jakob disease. J. Virol. 65:6292-6295.
28. Montrasio, F., et al. 2000. Impaired prion replication in spleens of mice lacking functional follicular dendritic cells. Science. 288:1257-1259.
29. Mabbott, N.A., Mackay, F., Minns, F., and Bruce, M.E. 2000. Temporary inactivation of follicular dendritic cells delays neuroinvasion of scrapie [letter]. Nat. Med. 6:719-720.
30. Klein, M.A., et al. 2001. Complement facilitates early prion pathogenesis. Nat. Med. 7:488-492.
31. Mabbott, N.A., Bruce, M.E., Botto, M., Walport, M.J., and Pepys, M.B. 2001. Temporary depletion of complement component C3 or genetic deficiency of Clq significantly delays onset of scrapie. Nat. Med. 7:485-487.
32. Felten, D.L., and Felten, S.Y. 1988. Sympathetic noradrenergic innervation of immune organs. Brain Behav. Immun. 2:293-300.
33. Glatzel, M., Heppner, F.L., Albers, K.M., and Aguzzi, A. 2001. Sympathetic innervation of lymphoreticular organs is rate limiting for prion neuroinvasion. Neuron. 31:25-34.
34. Heinen, E., Bosseloir, A., and Bouzahzah, F. 1995. Follicular dendritic cells: origin and function. Curr. Top. Microbiol. Immunol. 201:15-47.
35. Forster, R., et al. 1996. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell. 87:1037-1047.
36. Prinz, M., et al. 2003. Positioning of follicular dendritic cells within the spleen controls prion neuroinvasion. Nature. 425:957-962.
37. Aguzzi, A., and Polymenidou, M. 2004. Mammalian prion biology. One century of evolving concepts. Cell. 116:313-327.
38. Mallucci, G., et al. 2003. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science. 302:871-874.
39. Büeler, H.R., et al. 1992. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature. 356:577-582.
40. Mallucci, GR, et al. 2002. Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration. EMBO J. 21:202-210.
41. Ma, J., Wollmann, R., and Lindquist, S. 2002. Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science. 298:1781-1785.
42. Ma, J., and Lindquist, S. 2002. Conversion of PrP to a self-perpetuating PrPSc-like conformation in the cytosol. Science. 298:1785-1788.
43. Drisaldi, B., et al. 2003. Mutant PrP is delayed in its exit from the endoplasmic reticulum, but neither wild-type nor mutant PrP undergoes retrotranslocation prior to proteasomal degradation. J. Biol. Chem. 278:21732-21743.
44. Roucou, X., Guo, Q., Zhang, Y., Goodyer, C.G., and LeBlanc, A.C. 2003. Cytosolic prion protein is not toxic and protects against Bax-mediated cell death in human primary neurons. J. Biol. Chem. 278:40877-40881.
45. Hegde, R.S., et al. 1998. A transmembrane form of the prion protein in neurodegenerative disease. Science. 279:827-834.
46. Hegde, R.S., et al. 1999. Transmissible and genetic prion diseases share a common pathway of neurodegeneration. Nature. 402:822-826.
47. Shmerling, D., et al. 1998. Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions. Cell. 93:203-214.
48. Houston, F., Foster, J.D., Chong, A., Hunter, N., and Bostock, C.J. 2000. Transmission of BSE by blood transfusion in sheep. Lancet. 356:999-1000.
49. Hunter, N., et al. 2002. Transmission of prion diseases by blood transfusion. J. Gen. Virol. 83:2897-2905.
50. Aguzzi, A. 2000. Prion diseases, blood and the immune system: concerns and reality. Haematologica. 85:3-10.
51. Korth, C., et al. 1997. Prion (PrPSc)-specific epitope defined by a monoclonal antibody. Nature. 390:74-77.
52. Paramithiotis, E., et al. 2003. A prion protein epitope selective for the pathologically misfolded conformation. Nat. Med. 9:893-899.
53. Hsiao, K.K., et al. 1994. Serial transmission in rodents of neurodegeneration from transgenic mice expressing mutant prion protein. Proc. Natl. Acad. Sci. U. S. A. 91:9126-9130.
54. Lasmezas, C.I., et al. 1997. Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein. Science. 275:402-405.
55. Tagliavini, F., et al. 1994. Amyloid fibrits in Gerstmann-Straussler- Scheinker disease (Indiana and Swedish kindreds) express only PrP peptides encoded by the mutant allele. Cell. 79:695-703.
56. Duguid, J.R., and Dinauer, M.C. 1990. Library subtraction of in vitro cDNA libraries to identify differentially expressed genes in scrapie infection. Nucleic Acids Res. 18:2789-2792.
57. Duguid, J., and Trzepacz, C. 1993. Major histocompatibility complex genes have an increased brain expression after scrapie infection. Proc. Natl. Acad. Sci. U. S. A. 90:114-117.
58. Dandoy-Dron, F., et al. 1998. Gene expression in scrapie. Cloning of a new scrapie-responsive gene and the identification of increased levels of seven other mRNA transcripts. J. Biol. Chem. 273:7691-7697.
59. Miele, G., Manson, J., and Clinton, M. 2001. A novel erythroid-specific marker of transmissible spongiform encephalopathies. Nat. Med. 7:361-364.
60. Glock, B., et al. 2003. Transcript level of erythroid differentiation-related factor, a candidate surrogate marker for transmissible spongiform encephalopathy diseases in blood, shows a broad range of variation in healthy individuals. Transfusion, 43:1706-1710.
61. Tribl, G.G., et al. 2002. Sequential MRI in a case of Creutzfeldt-Jakob disease. Neuroradiology. 44:223-226.
62. Zeidler, M., Collie, D.A., Macleod, M.A., Sellar, R.J., and Knight, R. 2001. FLAIR MRI in sporadic Creutzfeldt-Jakob disease. Neurology. 56:282.
63. Hsich, G., Kinney, K., Gibbs, C.J., Lee, K.H., and Harrington, M.G. 1996. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N. Engl. J. Med. 335:924-930.
64. Beaudry, P., et al. 1999. 14-3-3 protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Dement. Geriatr. Cogn. Disord. 10:40-46.
65. Zerr, I., et al. 1998. Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann. Neurol. 43:32-40.
66. Aguzzi, A., and Weissmann, C. 1997. Prion research: the next frontiers. Nature. 389:795-798.
67. Klohn, P.C., Stoltze, L., Flechsig, E., Enari, M., and Weissmann, C. 2003. A quantitative, highly sensitive cell-based infectivity assay for mouse scrapie prions. Proc. Natl. Acad. Sci. U. S. A. 100:11666-11671.
68. Caughey, B., and Race, R.E. 1992. Potent inhibition of scrapie-associated PrP accumulation by congo red. J. Neurochem. 59:768-771.
69. Tagliavini, F., et al. 1997. Effectiveness of anthracycline against experimental prion disease in Syrian hamsters. Science. 276:1119-1122.
70. Caughey, B., and Raymond, G.J. 1993. Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. J. Virol. 67:643-650.
71. Priola, S.A., Raines, A., and Caughey, W.S. 2000. Porphyrin and phthalocyanine antiscrapie compounds. Science. 287:1503-1506.
72. Supattapone, S., et al. 2001. Branched polyamines cure prion-infected neuroblastoma cells. J. Virol. 75:3453-3461.
73. Soto, C., et al. 2000. Reversion of prion protein conformational changes by synthetic beta-sheet breaker peptides. Lancet. 355:192-197.
74. Caughey, B., et al. 2003. Inhibition of protease-resistant prion protein accumulation in vitro by curcumin. J. Virol. 77:5499-5502.
75. Daude, N., Marella, M., and Chabry, J. 2003. Specific inhibition of pathological prion protein accumulation by small interfering RNAs. J. Cell. Sci. 116:2775-2779.
76. Sethi, S., Lipford, G., Wagner, H., and Kretzschmar, H. 2002. Postexposure prophylaxis against prion disease with a stimulator of innate immunity. Lancet. 360:229-230.
77. Frigg, R., Klein, M.A., Hegyi, I., Zinkernagel, RM., and Aguzzi, A. 1999. Scrapie pathogenesis in sub-clinically infected B-cell-deficient mice. J. Virol. 73:9584-9588.
78. Prinz, M., et al. 2003. Prion pathogenesis in the absence of Toll-like receptor signalling. EMBO Rep. 4:195-199.
79. Heikenwalder, M., et al. 2004. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat. Med. 10:187-192.
80. Peretz, D., et al. 2001. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature. 412:739-743.
81. Enari, M., Flechsig, E., and Weissmann, C. 2001. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc. Natl. Acad. Sci. U. S. A. 98:9295-9299.
82. Souan, L., et al. 2001. Modulation of proteinase-K resistant prion protein by prion peptide immunization. Eur J. Immunol. 31:2338-2346.
83. Heppner, F.L., et al. 2001. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science. 294:178-182.
84. White, A.R., et al. 2003. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature. 422:80-83.
85. Solforosi, L., et al. 2004. Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science. 303:1514-1516.
86. Mead, S., et al. 2003. Balancing selection at the prion protein gene consistent with prehistoric kurulike epidemics. Science. 300:640-643.
87. Meier, P., et al. 2003. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease. Cell. 113:49-60.
88. Ladogana, A., et al. 1992. Sulphate polyanions prolong the incubation period of scrapie-infected hamsters. J. Gen. Virol. 73:661-665.
89. Prusiner, S.B., et al. 1983. Scrapie prions aggregate to form amyloid-like birefringent rods. Cell. 35:349-358.
90. Caughey, B., Ernst, D., and Race, R.E. 1993. Congo red inhibition of scrapie agent replication. J. Virol. 67:6270-6272.
91. Pocchiari, M., Schmittinger, S., and Masullo, C. 1987. Amphotericin B delays the incubation period of scrapie in intracerebrally inoculated hamsters. J. Gen. Virol. 68:219-223.
92. Mange, A., et al. 2000. Amphotericin B inhibits the generation of the scrapie isoform of the prion protein in infected cultures. J. Virol. 74:3135-3140.
93. Korth, C., May, B.C., Cohen, F.E., and Prusiner, S.B. 2001. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc. Natl. Acad. Sci. U. S. A. 98:9836-9841.
94. Barret, A., et al. 2003. Evaluation of quinacrine treatment for prion diseases. J. Virol. 77:8462-8469.
95. Bach, S., et al. 2003. Isolation of drugs active against mammalian prions using a yeast-based screening assay. Nat. Biotechnol. 21:1075-1081.